CovidChloroV1, Main, Exploration, bibRecord, 000A41

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.

Identifieur interne : 000A41 ( Main/Exploration ); précédent : 000A40; suivant : 000A42

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.

Auteurs : Samia Arshad [États-Unis] ; Paul Kilgore [États-Unis] ; Zohra S. Chaudhry [États-Unis] ; Gordon Jacobsen [États-Unis] ; Dee Dee Wang [États-Unis] ; Kylie Huitsing [États-Unis] ; Indira Brar [États-Unis] ; George J. Alangaden [États-Unis] ; Mayur S. Ramesh [États-Unis] ; John E. Mckinnon [États-Unis] ; William O'Neill [États-Unis] ; Marcus Zervos [États-Unis]

Source :

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [ 1878-3511 ] ; 2020.

RBID : pubmed:32623082

Descripteurs français

KwdFr :
- Adulte d'âge moyen (MeSH), Association de médicaments (MeSH), Azithromycine (usage thérapeutique), Betacoronavirus (MeSH), Facteurs de risque (MeSH), Femelle (MeSH), Hospitalisation (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Infections à coronavirus (mortalité), Infections à coronavirus (traitement médicamenteux), Mortalité hospitalière (MeSH), Mâle (MeSH), Pandémies (MeSH), Patients hospitalisés (MeSH), Pneumopathie virale (mortalité), Pneumopathie virale (traitement médicamenteux), Sujet âgé (MeSH), Études rétrospectives (MeSH).
MESH :
- mortalité : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Azithromycine, Hydroxychloroquine.
- Adulte d'âge moyen, Association de médicaments, Betacoronavirus, Facteurs de risque, Femelle, Hospitalisation, Humains, Mortalité hospitalière, Mâle, Pandémies, Patients hospitalisés, Sujet âgé, Études rétrospectives.

English descriptors

KwdEn :
- Aged (MeSH), Azithromycin (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (mortality), Drug Therapy, Combination (MeSH), Female (MeSH), Hospital Mortality (MeSH), Hospitalization (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Inpatients (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (mortality), Retrospective Studies (MeSH), Risk Factors (MeSH), SARS-CoV-2 (MeSH).
MESH :
- chemical , therapeutic use : Azithromycin, Hydroxychloroquine.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- Aged, Betacoronavirus, COVID-19, Drug Therapy, Combination, Female, Hospital Mortality, Hospitalization, Humans, Inpatients, Male, Middle Aged, Pandemics, Retrospective Studies, Risk Factors, SARS-CoV-2.

Abstract

SIGNIFICANCE

The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies.

OBJECTIVE

The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19.

DESIGN

Multi-center retrospective observational study.

SETTING

The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health system; the largest of hospitals is an 802-bed quaternary academic teaching hospital in urban Detroit, Michigan.

PARTICIPANTS

Consecutive patients hospitalized with a COVID-related admission in the health system from March 10, 2020 to May 2, 2020 were included. Only the first admission was included for patients with multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients for at least 48h unless expired within 24h.

EXPOSURE

Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin, azithromycin alone, or neither.

MAIN OUTCOME

The primary outcome was in-hospital mortality.

RESULTS

Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3-53). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine+azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]). Primary cause of mortality was respiratory failure (88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of mortality were age>65 years (HR:2.6 [95% CI:1.9-3.3]), white race (HR:1.7 [95% CI:1.4-2.1]), CKD (HR:1.7 [95%CI:1.4-2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1-2.1]), and ventilator use during admission (HR: 2.2 [95%CI:1.4-3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction, and hydroxychloroquine+azithromycin 71% compared to neither treatment (p<0.001).

CONCLUSIONS AND RELEVANCE

In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.

DOI: 10.1016/j.ijid.2020.06.099
PubMed: 32623082
PubMed Central: PMC7330574

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001233
to stream Main, to step Curation: 001233

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.</title>
<author><name sortKey="Arshad, Samia" sort="Arshad, Samia" uniqKey="Arshad S" first="Samia" last="Arshad">Samia Arshad</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kilgore, Paul" sort="Kilgore, Paul" uniqKey="Kilgore P" first="Paul" last="Kilgore">Paul Kilgore</name>
<affiliation wicri:level="2"><nlm:affiliation>Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chaudhry, Zohra S" sort="Chaudhry, Zohra S" uniqKey="Chaudhry Z" first="Zohra S" last="Chaudhry">Zohra S. Chaudhry</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacobsen, Gordon" sort="Jacobsen, Gordon" uniqKey="Jacobsen G" first="Gordon" last="Jacobsen">Gordon Jacobsen</name>
<affiliation wicri:level="2"><nlm:affiliation>Public Health Sciences, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Public Health Sciences, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Dee Dee" sort="Wang, Dee Dee" uniqKey="Wang D" first="Dee Dee" last="Wang">Dee Dee Wang</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Huitsing, Kylie" sort="Huitsing, Kylie" uniqKey="Huitsing K" first="Kylie" last="Huitsing">Kylie Huitsing</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brar, Indira" sort="Brar, Indira" uniqKey="Brar I" first="Indira" last="Brar">Indira Brar</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alangaden, George J" sort="Alangaden, George J" uniqKey="Alangaden G" first="George J" last="Alangaden">George J. Alangaden</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ramesh, Mayur S" sort="Ramesh, Mayur S" uniqKey="Ramesh M" first="Mayur S" last="Ramesh">Mayur S. Ramesh</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mckinnon, John E" sort="Mckinnon, John E" uniqKey="Mckinnon J" first="John E" last="Mckinnon">John E. Mckinnon</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Neill, William" sort="O Neill, William" uniqKey="O Neill W" first="William" last="O'Neill">William O'Neill</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zervos, Marcus" sort="Zervos, Marcus" uniqKey="Zervos M" first="Marcus" last="Zervos">Marcus Zervos</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI, United States. Electronic address: MZervos1@hfhs.org.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32623082</idno>
<idno type="pmid">32623082</idno>
<idno type="doi">10.1016/j.ijid.2020.06.099</idno>
<idno type="pmc">PMC7330574</idno>
<idno type="wicri:Area/Main/Corpus">001233</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001233</idno>
<idno type="wicri:Area/Main/Curation">001233</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001233</idno>
<idno type="wicri:Area/Main/Exploration">001233</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.</title>
<author><name sortKey="Arshad, Samia" sort="Arshad, Samia" uniqKey="Arshad S" first="Samia" last="Arshad">Samia Arshad</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kilgore, Paul" sort="Kilgore, Paul" uniqKey="Kilgore P" first="Paul" last="Kilgore">Paul Kilgore</name>
<affiliation wicri:level="2"><nlm:affiliation>Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chaudhry, Zohra S" sort="Chaudhry, Zohra S" uniqKey="Chaudhry Z" first="Zohra S" last="Chaudhry">Zohra S. Chaudhry</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jacobsen, Gordon" sort="Jacobsen, Gordon" uniqKey="Jacobsen G" first="Gordon" last="Jacobsen">Gordon Jacobsen</name>
<affiliation wicri:level="2"><nlm:affiliation>Public Health Sciences, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Public Health Sciences, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Dee Dee" sort="Wang, Dee Dee" uniqKey="Wang D" first="Dee Dee" last="Wang">Dee Dee Wang</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Huitsing, Kylie" sort="Huitsing, Kylie" uniqKey="Huitsing K" first="Kylie" last="Huitsing">Kylie Huitsing</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brar, Indira" sort="Brar, Indira" uniqKey="Brar I" first="Indira" last="Brar">Indira Brar</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Alangaden, George J" sort="Alangaden, George J" uniqKey="Alangaden G" first="George J" last="Alangaden">George J. Alangaden</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ramesh, Mayur S" sort="Ramesh, Mayur S" uniqKey="Ramesh M" first="Mayur S" last="Ramesh">Mayur S. Ramesh</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mckinnon, John E" sort="Mckinnon, John E" uniqKey="Mckinnon J" first="John E" last="Mckinnon">John E. Mckinnon</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="O Neill, William" sort="O Neill, William" uniqKey="O Neill W" first="William" last="O'Neill">William O'Neill</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zervos, Marcus" sort="Zervos, Marcus" uniqKey="Zervos M" first="Marcus" last="Zervos">Marcus Zervos</name>
<affiliation wicri:level="2"><nlm:affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI, United States. Electronic address: MZervos1@hfhs.org.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</title>
<idno type="eISSN">1878-3511</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term>
<term>Azithromycin (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (mortality)</term>
<term>Drug Therapy, Combination (MeSH)</term>
<term>Female (MeSH)</term>
<term>Hospital Mortality (MeSH)</term>
<term>Hospitalization (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Inpatients (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (mortality)</term>
<term>Retrospective Studies (MeSH)</term>
<term>Risk Factors (MeSH)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term>
<term>Association de médicaments (MeSH)</term>
<term>Azithromycine (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Hospitalisation (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Infections à coronavirus (mortalité)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Mortalité hospitalière (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Patients hospitalisés (MeSH)</term>
<term>Pneumopathie virale (mortalité)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Sujet âgé (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azithromycin</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Azithromycine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Hospital Mortality</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Inpatients</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pandemics</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Association de médicaments</term>
<term>Betacoronavirus</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Hospitalisation</term>
<term>Humains</term>
<term>Mortalité hospitalière</term>
<term>Mâle</term>
<term>Pandémies</term>
<term>Patients hospitalisés</term>
<term>Sujet âgé</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>SIGNIFICANCE</b>
</p>
<p>The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>DESIGN</b>
</p>
<p>Multi-center retrospective observational study.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>SETTING</b>
</p>
<p>The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health system; the largest of hospitals is an 802-bed quaternary academic teaching hospital in urban Detroit, Michigan.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>PARTICIPANTS</b>
</p>
<p>Consecutive patients hospitalized with a COVID-related admission in the health system from March 10, 2020 to May 2, 2020 were included. Only the first admission was included for patients with multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients for at least 48h unless expired within 24h.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>EXPOSURE</b>
</p>
<p>Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin, azithromycin alone, or neither.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>MAIN OUTCOME</b>
</p>
<p>The primary outcome was in-hospital mortality.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3-53). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine+azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]). Primary cause of mortality was respiratory failure (88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of mortality were age>65 years (HR:2.6 [95% CI:1.9-3.3]), white race (HR:1.7 [95% CI:1.4-2.1]), CKD (HR:1.7 [95%CI:1.4-2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1-2.1]), and ventilator use during admission (HR: 2.2 [95%CI:1.4-3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction, and hydroxychloroquine+azithromycin 71% compared to neither treatment (p<0.001).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS AND RELEVANCE</b>
</p>
<p>In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32623082</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>97</Volume>
<PubDate><Year>2020</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title>
<ISOAbbreviation>Int J Infect Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>396-403</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1201-9712(20)30534-8</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2020.06.099</ELocationID>
<Abstract><AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19.</AbstractText>
<AbstractText Label="DESIGN" NlmCategory="METHODS">Multi-center retrospective observational study.</AbstractText>
<AbstractText Label="SETTING" NlmCategory="METHODS">The Henry Ford Health System (HFHS) in Southeast Michigan: large six hospital integrated health system; the largest of hospitals is an 802-bed quaternary academic teaching hospital in urban Detroit, Michigan.</AbstractText>
<AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Consecutive patients hospitalized with a COVID-related admission in the health system from March 10, 2020 to May 2, 2020 were included. Only the first admission was included for patients with multiple admissions. All patients evaluated were 18 years of age and older and were treated as inpatients for at least 48h unless expired within 24h.</AbstractText>
<AbstractText Label="EXPOSURE" NlmCategory="METHODS">Receipt of hydroxychloroquine alone, hydroxychloroquine in combination with azithromycin, azithromycin alone, or neither.</AbstractText>
<AbstractText Label="MAIN OUTCOME" NlmCategory="RESULTS">The primary outcome was in-hospital mortality.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 2,541 patients, with a median total hospitalization time of 6 days (IQR: 4-10 days), median age was 64 years (IQR:53-76 years), 51% male, 56% African American, with median time to follow-up of 28.5 days (IQR:3-53). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine+azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]). Primary cause of mortality was respiratory failure (88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of mortality were age>65 years (HR:2.6 [95% CI:1.9-3.3]), white race (HR:1.7 [95% CI:1.4-2.1]), CKD (HR:1.7 [95%CI:1.4-2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1-2.1]), and ventilator use during admission (HR: 2.2 [95%CI:1.4-3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction, and hydroxychloroquine+azithromycin 71% compared to neither treatment (p<0.001).</AbstractText>
<AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Prospective trials are needed to examine this impact.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arshad</LastName>
<ForeName>Samia</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kilgore</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Eugene Applebaum College of Pharmacy, Wayne State University, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chaudhry</LastName>
<ForeName>Zohra S</ForeName>
<Initials>ZS</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jacobsen</LastName>
<ForeName>Gordon</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Public Health Sciences, Henry Ford Hospital, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Dee Dee</ForeName>
<Initials>DD</Initials>
<AffiliationInfo><Affiliation>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Huitsing</LastName>
<ForeName>Kylie</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Brar</LastName>
<ForeName>Indira</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Alangaden</LastName>
<ForeName>George J</ForeName>
<Initials>GJ</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ramesh</LastName>
<ForeName>Mayur S</ForeName>
<Initials>MS</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McKinnon</LastName>
<ForeName>John E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>O'Neill</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Division of Cardiovascular Disease & Structural Heart, Henry Ford Hospital, Detroit, MI, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zervos</LastName>
<ForeName>Marcus</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States; Wayne State University School of Medicine, Detroit, MI, United States. Electronic address: MZervos1@hfhs.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>Henry Ford COVID-19 Task Force</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D064888">Observational Study</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>07</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Canada</Country>
<MedlineTA>Int J Infect Dis</MedlineTA>
<NlmUniqueID>9610933</NlmUniqueID>
<ISSNLinking>1201-9712</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Int J Infect Dis. 2020 Oct;99:38-39</RefSource>
<PMID Version="1">32738483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Int J Infect Dis. 2020 Oct;99:310-311</RefSource>
<PMID Version="1">32738490</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Int J Infect Dis. 2020 Oct;99:75-76</RefSource>
<PMID Version="1">32738491</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Int J Infect Dis. 2020 Oct;99:37</RefSource>
<PMID Version="1">32738492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Int J Infect Dis. 2020 Oct;99:344-345</RefSource>
<PMID Version="1">32768694</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Int J Infect Dis. 2020 Oct;99:324</RefSource>
<PMID Version="1">32768698</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Int J Infect Dis. 2020 Oct;99:373</RefSource>
<PMID Version="1">32771630</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">Mortality</Keyword>
<Keyword MajorTopicYN="N">SARS-COV-2</Keyword>
<Keyword MajorTopicYN="N">Therapy</Keyword>
</KeywordList>
<InvestigatorList><Investigator ValidYN="Y"><LastName>Nauriyal</LastName>
<ForeName>Varidhi</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hamed</LastName>
<ForeName>Asif Abdul</ForeName>
<Initials>AA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Nadeem</LastName>
<ForeName>Owais</ForeName>
<Initials>O</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Swiderek</LastName>
<ForeName>Jennifer</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Godfrey</LastName>
<ForeName>Amanda</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Jennings</LastName>
<ForeName>Jeffrey</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gardner-Gray</LastName>
<ForeName>Jayna</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ackerman</LastName>
<ForeName>Adam M</ForeName>
<Initials>AM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lezotte</LastName>
<ForeName>Jonathan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ruhala</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fadel</LastName>
<ForeName>Raef</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vahia</LastName>
<ForeName>Amit</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gudipati</LastName>
<ForeName>Smitha</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Parraga</LastName>
<ForeName>Tommy</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Shallal</LastName>
<ForeName>Anita</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Maki</LastName>
<ForeName>Gina</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tariq</LastName>
<ForeName>Zain</ForeName>
<Initials>Z</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Suleyman</LastName>
<ForeName>Geehan</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Yared</LastName>
<ForeName>Nicholas</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Herc</LastName>
<ForeName>Erica</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Williams</LastName>
<ForeName>Johnathan</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lanfranco</LastName>
<ForeName>Odaliz Abreu</ForeName>
<Initials>OA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bhargava</LastName>
<ForeName>Pallavi</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Reyes</LastName>
<ForeName>Katherine</ForeName>
<Initials>K</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>06</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32623082</ArticleId>
<ArticleId IdType="pii">S1201-9712(20)30534-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.ijid.2020.06.099</ArticleId>
<ArticleId IdType="pmc">PMC7330574</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>JAMA. 2020 Apr 14;323(14):1339-1340</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32108857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microb Pathog. 2020 Aug;145:104228</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32344177</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32284951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):887-888</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32211764</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 26;323(20):2052-2059</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32320003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1612-1614</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32191259</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2010 Mar;62(3):863-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20131232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101738</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32387409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med (N Y). 2020 Dec 18;1(1):114-127.e3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Disaster Med Public Health Prep. 2010 Dec;4(4):277-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21149228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antibiot (Tokyo). 2019 Oct;72(10):759-768</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31300721</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 12;323(18):1824-1836</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc (Bayl Univ Med Cent). 2020 May 14;33(3):481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32675999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Michigan</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Michigan"><name sortKey="Arshad, Samia" sort="Arshad, Samia" uniqKey="Arshad S" first="Samia" last="Arshad">Samia Arshad</name>
</region>
<name sortKey="Alangaden, George J" sort="Alangaden, George J" uniqKey="Alangaden G" first="George J" last="Alangaden">George J. Alangaden</name>
<name sortKey="Brar, Indira" sort="Brar, Indira" uniqKey="Brar I" first="Indira" last="Brar">Indira Brar</name>
<name sortKey="Chaudhry, Zohra S" sort="Chaudhry, Zohra S" uniqKey="Chaudhry Z" first="Zohra S" last="Chaudhry">Zohra S. Chaudhry</name>
<name sortKey="Huitsing, Kylie" sort="Huitsing, Kylie" uniqKey="Huitsing K" first="Kylie" last="Huitsing">Kylie Huitsing</name>
<name sortKey="Jacobsen, Gordon" sort="Jacobsen, Gordon" uniqKey="Jacobsen G" first="Gordon" last="Jacobsen">Gordon Jacobsen</name>
<name sortKey="Kilgore, Paul" sort="Kilgore, Paul" uniqKey="Kilgore P" first="Paul" last="Kilgore">Paul Kilgore</name>
<name sortKey="Mckinnon, John E" sort="Mckinnon, John E" uniqKey="Mckinnon J" first="John E" last="Mckinnon">John E. Mckinnon</name>
<name sortKey="O Neill, William" sort="O Neill, William" uniqKey="O Neill W" first="William" last="O'Neill">William O'Neill</name>
<name sortKey="Ramesh, Mayur S" sort="Ramesh, Mayur S" uniqKey="Ramesh M" first="Mayur S" last="Ramesh">Mayur S. Ramesh</name>
<name sortKey="Wang, Dee Dee" sort="Wang, Dee Dee" uniqKey="Wang D" first="Dee Dee" last="Wang">Dee Dee Wang</name>
<name sortKey="Zervos, Marcus" sort="Zervos, Marcus" uniqKey="Zervos M" first="Marcus" last="Zervos">Marcus Zervos</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A41 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A41 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32623082
   |texte=   Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32623082" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki